FDA committee supports Nordisk ’ s cardiovascular risk claim for Victoza label
Novo Nordisk (NYSE:NVO) shares ticked up 1% earlier this week after an advisory committee for the FDA voted to recommend that the company’s cardiovascular risk reduction claim be added to its Victoza (liraglutide) label.
The discussions among committee members involved data from the 9,300-patient Leader trial, which involved people with Type II diabetes at high risk of major cardiovascular events.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA committee supports Nordisk’s cardiovascular risk claim for Victoza label appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news
FDA Panel Backs Liraglutide to Reduce CV Risk Factors FDA Panel Backs Liraglutide to Reduce CV Risk Factors
An FDA panel recommended liraglutide for the additional indication of reducing the risk for major adverse cardiovascular events in adults with type 2 diabetes mellitus and high cardiovascular risk.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
FDA Panel Says Yes to CV Indication for Liraglutide
(MedPage Today) -- But questioned lack of benefit in U.S. subgroup in LEADER trial (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 20, 2017 Category: American Health Source Type: news
Clear Sailing Likely for Victoza CV Indication
(MedPage Today) -- No major issues put forth for Tuesday FDA advisory committee (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - June 19, 2017 Category: Urology & Nephrology Source Type: news
Clear Sailing Likely for Liraglutide CV Indication
(MedPage Today) -- No major issues put forth for Tuesday FDA advisory committee (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 19, 2017 Category: American Health Source Type: news
Novo Nordisk Looks to Expand Latin American Obesity Business Novo Nordisk Looks to Expand Latin American Obesity Business
Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of"phenomenal" performance by its new anti-obesity injection Saxenda (liraglutide), a senior company official said on Monday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes.
In clinical trials, Xultophy reduced A1C and lowered blood sugar for 24 hours, according to Nordisk.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk launches Xultophy diabetes therapy in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news
Liraglutide cost effective for T2DM in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2017 Category: Drugs & Pharmacology Source Type: news
Nordisk wins label update for weight loss drug-device combo
Novo Nordisk (NYSE:NVO) said today that the FDA approved an updated label for its Saxenda liraglutide weight loss medicine. The therapy’s new label will include data showing that half of patients who received Saxenda and lost at least 5% of their weight after 56 weeks maintained their weight loss for 3 years.
The update is based on data from the company’s Scale obesity and pre-diabetes 3-year trial, which evaluated the long-term safety and efficacy of Saxenda in 3,731 adults.
Get the full story at our sister site, Drug Delivery Business News.
The post Nordisk wins label update for weight loss drug-device combo appeare...
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news
ENDO: Liraglutide May Prevent Lipolysis, Ketogenesis in T1D (CME/CE)
(MedPage Today) -- Favorable results from placebo-controlled trial (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 6, 2017 Category: Consumer Health News Source Type: news
Effect of Liraglutide on Liver Fat in Poorly Controlled T2D Effect of Liraglutide on Liver Fat in Poorly Controlled T2D
A new study observes the changes in liver fat content associated with liraglutide treatment in patients with uncontrolled type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Could a diabetes drug be used for Motor Neurone Disease?
(Lancaster University) A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.Researchers at Lancaster University are to conduct a clinical trial of the diabetes drug Liraglutide, giving it to patients with MND to see whether they improve or not. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 10, 2017 Category: Global & Universal Source Type: news
Once-daily liraglutide cost effective for T2DM in the UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 28, 2017 Category: Drugs & Pharmacology Source Type: news
EndoBreak: Liraglutide for Prediabetes; Sugar Tax's Mixed Result; Diabetes Reversal
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 24, 2017 Category: Pediatrics Source Type: news
Weight loss drug could prevent type 2 diabetes
Liraglutide, a weight loss drug, reduced type 2 diabetes risk in at-risk patients by 80%, according to a study published inThe Lancet.Express (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news
